Mizuho raised the firm’s price target on Axsome Therapeutics to $109 from $108 and keeps a Buy rating on the shares. The analyst sees a “significant data catalyst” in the second half of 2024 with the ADVANCE-2 data for AXS-05 in Alzheimer’s agitation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- 3 Best Stocks to Buy Now, 3/27/2024, According to Top Analysts
- Axsome Therapeutics price target raised to $128 from $123 at RBC Capital
- Axsome Therapeutics price target raised to $190 from $180 at H.C. Wainwright
- Citi ups Axsome Therapeutics target, says selloff unwarranted
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
